At 1.0 mg weekly, a 10 mg vial lasts 10 weeks
Most patients experience fewer gastrointestinal issues after 46 weeks as their bodies adapt to semaglutide dosing
The precision nasal spray formulation offers researchers a reproducible method for evaluating intranasal administration while supporting consistent delivery throughout laboratory protocols
Some patients report sulfur burps and diarrhea semaglutide, particularly in the early stages of treatment
however, their administration is frequently accompanied by adverse events, predominantly gastrointestinal.218,219 Specifically, GLP-1RAs have been strongly linked to gastrointestinal symptoms, such as nausea, vomiting, and diarrhea, with incidence rates influenced by dosage and concomitant therapies.78 Moreover, the use of GLP-1RAs may be associated with an elevated risk of pancreatitis and thyroid-related disorders, although these associations have not been definitively established.220 Analysis of data from the US Food and Drug Administration Adverse Event Reporting System revealed that GLP-1RAs, particularly semaglutide and exenatide, are significantly correlated with gastrointestinal adverse events, including nausea, vomiting, delayed gastric emptying, and pancreatitis.221 Dual receptor agonists targeting GLP-1 and GIP, such as tirzepatide, have also exhibited promising efficacy in diabetes management, notably in terms of weight reduction and glycemic control
However, patient's expectations, treatment satisfaction and the outcomes achieved are also relevant and should be considered [9, 20]
